Rapid skin improvement with upadacitinib with or without topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

被引：0
|
作者：
Simpson, Eric L. [1 ]
Warren, Richard B. [2 ]
Eichenfield, Lawrence F. [3 ,4 ]
Katoh, Norito [5 ]
Hu, Xiaofei [6 ]
Zeng, Jiewei [6 ]
Calimlim, Brian M. [6 ]
Tenorio, Allan R. [6 ]
Teixeira, Henrique D. [6 ]
De Bruin-Weller, Marjolein [7 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA
[2] Univ Manchester, Salford Royal NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Dermatol Ctr, Manchester, Lancs, England
[3] Univ Calif San Diego, Sch Med, Dept Dermatol, San Diego, CA USA
[4] Univ Calif San Diego, Sch Med, Dept Pediat, San Diego, CA USA
[5] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Dermatol, Kyoto, Japan
[6] AbbVie Inc, N Chicago, IL USA
[7] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27915
引用
收藏
页码：AB167 / AB167
页数：1
相关论文
共 50 条
  • [21] Ef-ficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD UpRandomized Clinical Trials
    Paller, Amy. S.
    JAMA DERMATOLOGY, 2024, 160 (05) : 582 - 582
  • [22] Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
    Silverberg, Jonathan I.
    Deleuran, Mette
    Gold, Linda S.
    Bunick, Christopher G.
    Hijnen, Dirk Jan
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Platt, Andrew M.
    Grada, Ayman
    Hu, Xiaofei
    Gooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB90 - AB90
  • [23] Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies
    Prajapati, Vimal H.
    Bunick, Christopher G.
    Eyerich, Kilian
    Gold, Linda Stein
    Galimberti, Fabrizio
    Calimlim, Brian
    Teixeira, Henrique
    Hu, Xiaofei
    Yang, Yang
    Sancho, Cristina
    Grada, Ayman
    Irvine, Alan D.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [24] Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results
    Silverberg, Jonathan, I
    De Bruin-Weller, Marjolein
    Bieber, Thomas
    Soong, Weily
    Kabashima, Kenji
    Costanzo, Antonio
    Rosmarin, David
    Lynde, Charles
    Liu, John
    Gamelli, Amy
    Zeng, Jiewei
    Ladizinski, Barry
    Chu, Alvina D.
    Reich, Kristian
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (03) : 977 - +
  • [25] Characterization of hematologic and transaminase laboratory findings associated with upadacitinib in moderate-to-severe atopic dermatitis: Results of two phase 3 trials (measure up 1 and 2)
    Silverberg, Jonathan I.
    Gooderham, Melinda J.
    de Bruin-Weller, Marjolein S.
    Papp, Kim A.
    Aoki, Valeria
    Paller, Amy S.
    Ofori, Sarah
    Tenorio, Allan R.
    Liu, Yingyi
    Liu, Jianzhong
    Chovatiya, Raj
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (08): : 1010 - 1010
  • [26] Achieving incrementally greater skin improvement thresholds with upadacitinib versus dupilumab in moderate-to-severe atopic dermatitis (AD): Heads Up study results
    Silverberg, Jonathan I.
    Eyerich, Kilian
    de Bruin-Weller, Marjolein
    Calimlim, Brian M.
    Platt, Andrew M.
    Wu, Tianshuang
    Ladizinski, Barry
    Thyssen, Jacob P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB134 - AB134
  • [27] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Reich, Kristian
    Teixeira, Henrique D.
    de Bruin-Weller, Marjolein
    Bieber, Thomas
    Soong, Weily
    Kabashima, Kenji
    Werfel, Thomas
    Zeng, Jiewei
    Huang, Xiaohong
    Hu, Xiaofei
    Hendrickson, Barbara A.
    Ladizinski, Barry
    Chu, Alvina D.
    Silverberg, Jonathan I.
    LANCET, 2021, 397 (10290): : 2169 - 2181
  • [28] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
    Simpson, Eric L.
    de Bruin-Weller, Marjolein S.
    Prajapati, Vimal H.
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Zeng, Jiewei
    Liu, Meng
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB60 - AB60
  • [29] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
    Guttman-Yassky, Emma
    Teixeira, Henrique D.
    Simpson, Eric L.
    Papp, Kim A.
    Pangan, Aileen L.
    Blauvelt, Andrew
    Thaci, Diamant
    Chu, Chia-Yu
    Hong, H. Chih-Ho
    Katoh, Norito
    Paller, Amy S.
    Calimlim, Brian
    Gu, Yihua
    Hu, Xiaofei
    Liu, Meng
    Yang, Yang
    Liu, John
    Tenorio, Allan R.
    Chu, Alvina D.
    Irvine, Alan D.
    LANCET, 2021, 397 (10290): : 2151 - 2168
  • [30] ABSOLUTE EASI TARGET IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF DATA FROM THE MEASURE UP 1 AND 2 STUDIES
    Prajapatil, Vimal
    Simpson, Eric L.
    Thyssen, Jacob P.
    Chovatiya, Raj
    Lane, Michael
    Teixeira, Henrique
    Calimlim, Brian
    Silverberg, Jonathan I.
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 33 - 33
12345